董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Francis | 男 | Director | 67 | 6.73万美元 | 63.63 | 2023-10-11 |
| Megan Boston | 女 | Executive Director, Director | 51 | 35.25万美元 | 10.00 | 2023-10-11 |
| Jerel A. Banks | 男 | Chief Executive Officer, Chairman of the Board | 48 | 64.57万美元 | 未持股 | 2023-10-11 |
| J. Kevin Buchi | 男 | Director | 68 | 6.58万美元 | 144.82 | 2023-10-11 |
| Edward Smith | 男 | Director | 52 | 6.30万美元 | 未持股 | 2023-10-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Megan Boston | 女 | Executive Director, Director | 51 | 35.25万美元 | 10.00 | 2023-10-11 |
| Jerel A. Banks | 男 | Chief Executive Officer, Chairman of the Board | 48 | 64.57万美元 | 未持股 | 2023-10-11 |
董事简历
中英对照 | 中文 | 英文- Peter Francis
-
Peter Francis自2006年2月成为公司的董事长。1993年起 Francis先生在Francis Abourizk Lightowlers（一家商业和技术律师事务所）和位于澳大利亚墨尔本（Melbourne, Australia）的办事处的合伙人。他是知识产权和许可领域的法律专家，为公司和研究机构提供法律咨询。Francis先生完成了他在莫纳什大学（Monash University）法律与判例课程。
Peter Francis has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993 Mr. Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr. Francis completed his studies in law and jurisprudence at Monash University. - Peter Francis自2006年2月成为公司的董事长。1993年起 Francis先生在Francis Abourizk Lightowlers（一家商业和技术律师事务所）和位于澳大利亚墨尔本（Melbourne, Australia）的办事处的合伙人。他是知识产权和许可领域的法律专家，为公司和研究机构提供法律咨询。Francis先生完成了他在莫纳什大学（Monash University）法律与判例课程。
- Peter Francis has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993 Mr. Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr. Francis completed his studies in law and jurisprudence at Monash University.
- Megan Boston
-
Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 13 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Specifically, Ms. Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms. Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors. - Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
- Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 13 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Specifically, Ms. Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms. Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.
- Jerel A. Banks
-
Jerel A. Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
Jerel A. Banks has been a Director since October 2016 Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011 Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. - Jerel A. Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
- Jerel A. Banks has been a Director since October 2016 Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011 Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University.
- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
- Edward Smith
-
Edward Smith自2020年4月起担任董事。史密斯先生目前担任MarinusPharmaceuticals，Inc.的首席财务官。纳斯达克股票代码:MRNS，一家临床阶段的制药公司，专注于开发和商业化创新疗法，以治疗患有罕见癫痫疾病的患者。2013年在Marinus Pharmaceuticals任职之前，Smith先生担任PolyMedix，Inc.的首席财务官，在PolyMedix，Inc.任职之前，他担任Inkine Pharmaceutical Company，Inc.的财务执行董事。
Edward Smith has been a director since April 2020. Edward served as the Chief Financial Officer of LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage pharmaceutical company focused on developing novel immuno-oncology therapeutics. Prior to that, he served as Chief Financial Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders, and PolyMedix, Inc., a clinical stage pharmaceutical company focused on developing a novel class of antibiotics for the treatment of infectious diseases. Before his time at PolyMedix, Inc. he served as the executive director of finance at InKine Pharmaceutical Company, Inc. and held various positions in public accounting, most recently in the audit practice of Deloitte. - Edward Smith自2020年4月起担任董事。史密斯先生目前担任MarinusPharmaceuticals，Inc.的首席财务官。纳斯达克股票代码:MRNS，一家临床阶段的制药公司，专注于开发和商业化创新疗法，以治疗患有罕见癫痫疾病的患者。2013年在Marinus Pharmaceuticals任职之前，Smith先生担任PolyMedix，Inc.的首席财务官，在PolyMedix，Inc.任职之前，他担任Inkine Pharmaceutical Company，Inc.的财务执行董事。
- Edward Smith has been a director since April 2020. Edward served as the Chief Financial Officer of LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage pharmaceutical company focused on developing novel immuno-oncology therapeutics. Prior to that, he served as Chief Financial Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders, and PolyMedix, Inc., a clinical stage pharmaceutical company focused on developing a novel class of antibiotics for the treatment of infectious diseases. Before his time at PolyMedix, Inc. he served as the executive director of finance at InKine Pharmaceutical Company, Inc. and held various positions in public accounting, most recently in the audit practice of Deloitte.
高管简历
中英对照 | 中文 | 英文- Megan Boston
Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 13 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Specifically, Ms. Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms. Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.- Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
- Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 13 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Specifically, Ms. Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms. Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.
- Jerel A. Banks
Jerel A. Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
Jerel A. Banks has been a Director since October 2016 Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011 Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University.- Jerel A. Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
- Jerel A. Banks has been a Director since October 2016 Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011 Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University.